Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
Recruiting now
Conditions studied: Small Bowel Adenocarcinoma
In brief
Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.
Key facts
- Study ID
- NCT06234306
- Run by
- Copenhagen University Hospital at Herlev
- People needed
- 500
- Starts
- 2024-01-01
- Expected to finish
- 2033-12-31
- Last updated by the study team
- 2024-01-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years
You may not qualify if…
- Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\&
- Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.
Where it is running
- Department of Oncology, Aarhus University Hospital — Aarhus N, Denmark (enrolling)
- Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet — Copenhagen Ø, Denmark (enrolling)
- Department of Oncology Copenhagen University Hospital - Herlev and Gentofte — Herlev, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.